News Scinai Immunotherapeutics Ltd.

Stocks

SCNI

US09073Q4029

Biotechnology & Medical Research

Market Closed - Nasdaq 01:30:00 03/11/2026 +04			5-day change	1st Jan Change
0.4742 ^USD	+0.55%		-12.43%	-93.34%

10-16	Scinai Immunotherapeutics Ltd. announced that it has received $2.95 million in funding	CI
10-14	Scinai Immunotherapeutics Ltd. announced that it expects to receive $2.95 million in funding	CI

All News

Mentions Relevance

10-16	Scinai Immunotherapeutics Ltd. announced that it has received $2.95 million in funding	CI
10-14	Scinai Immunotherapeutics Ltd. announced that it expects to receive $2.95 million in funding	CI
10-13	Scinai Immunotherapeutics Ltd. Expands Cdmo Business with Scinai Biopharma Services Ltd.'S $5.1 Million Development and Clinical Manufacturing Agreement	CI
09-09	Scinai Concludes PC111 Arrangements and Refocuses Capital on NanoAb Platform and Growing CDMO Business	AQ
08-26	Scinai Immunotherapeutics Ltd., H1 2026 Earnings Call, Aug 26, 2026
08-24	Scinai Immunotherapeutics Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-11	Scinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration	AQ
08-10	Scinai Biopharma Services Ltd. Wholly Owned Subsidiary of Scinai Immunotherapeutics Ltd. Announces Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration	CI
06-15	Scinai Immunotherapeutics Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-20	Scinai Immunotherapeutics Ltd. Appoints Eilon Elmalem as Site Head of Yavne Cdmo Facility, Effective June 14, 2026	CI
05-18	Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe	AQ
04-27	Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing	AQ
04-27	Scinai Immunotherapeutics Ltd. announced that it has received $2.5 million in funding	CI
04-24	Scinai Immunotherapeutics Ltd. announced that it expects to receive $2.5 million in funding	CI
04-06	Scinai completes strategic reorganization to establish dedicated CDMO platform and lean R&D structure; outlines 2026 priorities	RE
04-06	Scinai Immunotherapeutics Leverages Strategic Collaboration with Recipharm to Build Integrated Lifecycle CDMO Platform	CI
04-01	Scinai reports full-year 2025 results, with cdmo revenues doubling and strategic expansion through Recipharm collaboration	RE
04-01	Scinai Immunotherapeutics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-01	Scinai Immunotherapeutics Ltd. Auditor Raises 'Going Concern' Doubt	CI
03-19	Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026	PR
03-17	Scinai Immunotherapeutics receives Nasdaq notification regarding minimum bid price	RE
03-17	Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price	PR
03-02	Scinai signs second amendment to Pincell option agreement and submits revised EUR12 million non-dilutive Feng application to advance Pc111 through human proof of concept	RE
03-02	Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept	PR
02-25	Scinai Announces Expanded Israel Innovation Authority Support for Robotic Aseptic Fill & Finish Platform	CI